Seagen®

SGN-PDL1V

An investigational antibody-drug conjugate directed to PD-L1



Key Attributes

- Designed to limit potential immune-related toxicity via elimination of CDC, ADCC, and ADCP[1]
- Engineered for rapid internalization and delivery of cytotoxic MMAE to target cells[1]

Target: PD-L1

- A cell-surface protein that functions as an immune checkpoint[2-4]
- Expressed on tumor cells and directed to PD-1 on T cells to inhibit T-cell effector function[2]
- Overexpressed in multiple cancers (NSCLC, melanoma, HNSCC, TNBC, UC, and cervical, gastric, ovarian, and esophageal cancers)[1,4-17]
- Typically associated with poor prognosis[4-17]

Proposed Mechanism of Action[1,a]

- Direct cytotoxicity via microtubule disruption
- Bystander effect
- Immunogenic cell death

ADCC: antibody-dependent cellular cytotoxicity; **ADCP**: antibody-dependent cellular phagocytosis; **CDC**: complement-dependent cytotoxicity; **HNSCC**: head and neck squamous cell carcinoma; **mc-vc**: maleimidocaproyl-valine-citrulline; **IgG1**: immunoglobulin G1; **MMAE**: monomethyl auristatin E; **NSCLC**: non-small cell lung cancer; **PD-1**: programmed cell death protein 1; **PD-L1**: programmed death-ligand 1; **TNBC**: triple-negative breast cancer; **UC**: urothelial cancer

[a]Based on preclinical data

1. Kwan BH. SITC virtual 2021: 10-4. 2. Chen DS. Immunology. 2013: 1-10. 3. Pardoll DM. Nat Rev Cancer. 2012: 252-64. 4. O'Malley D. Ann Oncol. 2019: 425-6. 5. Cha JH. Mol Cell. 2019: 359-70. 6. Balar AV. Lancet Oncol. 2017: 1483-92. 7. Burtness B. Lancet. 2019: 1915-28. 8. Chung HC. J Clin Oncol. 2019: 1470-8. 9. Fuchs CS. JAMA Oncol. 2018: e180013. 10. Herbst RS. Lancet. 2016: 1540-50. 11. Mok TSK. Lancet. 2019: 1819-30. 12. Reck M. N Engl J Med. 2016: 1823-33. 13. Robert C. N Engl J Med. 2015: 320-30. 14. Schmid P. N Engl J Med. 2020: 810-21. 15. Shah MA. JAMA Oncol. 2019: 546-50. 16. Shitara K. Lancet. 2018: 123-33. 17. Varga A. Gynecol Oncol. 2019: 243-50.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

SGN-PDL1V

Proposed Mechanism of Action[1,a]

1. Binds to PD-L1
2. Complex internalization and trafficking
3. MMAE release
4. Microtubule disruption
5. Cell cycle arrest and apoptotic cell death



MMAE: monomethyl auristatin E; **PD-1**: programmed cell death protein 1; **PD-L1**: programmed death-ligand 1

[a]Based on preclinical data

1. Kwan BH. SITC virtual 2021: 10-4.

Clinical Trials

Phase 1 : Phase 2 : Phase 3

RECRUITING **SGNPDL1V-001: Advanced solid tumors**
(NCT05208762) SGN-PDL1V

Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Seagen and its logo are US registered trademarks of Seagen Inc.
Other trademarks are property of their respective owners.

© 2023 Seagen Inc., Bothell, WA 98021
Printed in the USA USM/PDL/2023/0003

For more information, contact us at:
+1-855-4SEAGEN (+1-855-473-2436)
medinfo@seagen.com / medinfoEU@seagen.com
www.seagenmedinfo.com